In 2019.0 RSC ADV published article about NATURAL-PRODUCTS; INVASION in [Li, Xiaojing; Wang, Na; Wang, Shuai; Wang, Hongmin] Liaocheng Univ, Sch Pharm, Lab Drug Discover & Design, Liaocheng 252000, Shandong, Peoples R China; [Li, Xiaojing] Shandong Univ, Sch Pharm, Minist Educ, Dept Med Chem,Key Lab Chem Biol, Jinan 250012, Shandong, Peoples R China; [Liu, Yihua; Ren, Shaoda] Liaocheng Peoples Hosp, Cent Lab, Liaocheng 252000, Shandong, Peoples R China; [Liu, Yuyu] Shandong Qidu Pharmaceut Co Ltd, Zibo 255400, Peoples R China; [Lie, Aihua] Liaocheng Peoples Hosp, Dept Obstet & Gynecol, Liaocheng 252000, Shandong, Peoples R China in 2019.0, Cited 23.0. The Name is Methyl 3-phenylpropionate. Through research, I have a further understanding and discovery of 103-25-3. Computed Properties of C10H12O2
Despite advances in ovarian cancer treatment, the five-year overall survival rate is less than 30% with the presence of cancer stem cells (CSCs). To develop CSC-targeting therapy, a series of 18 beta-glycyrrhetinic acid (GA) derivatives containing cinnamamide moiety have been designed, synthesized, and screened for their antiproliferative activity in SKOV3 and OVCAR3 cells. Most of the compounds exhibited stronger antiproliferative activity than GA, and compound 7c was the most active one. Further biological studies showed that compound 7c could induce apoptosis and suppress migration. In addition, compound 7c could not only observably decrease the colony formation and sphere formation ability, but also significantly reduce the CD44(+), CD133(+), and ALDH(+) subpopulation in SKOV3 and OVCAR3 cells. In conclusion, these results indicate that compound 7c is a promising anti-CSC agent for further anti-ovarian cancer studies.
About Methyl 3-phenylpropionate, If you have any questions, you can contact Li, XJ; Liu, YH; Wang, N; Liu, YY; Wang, S; Wang, HM; Lie, AH; Ren, SD or concate me.. Computed Properties of C10H12O2
Reference:
Patent; SANOFI; US2011/294788; (2011); A1;,
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics